Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
LPL Double Nickase Plasmid (h): sc-400751-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- LPL Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- LPL Double Nickase Plasmid (h) and LPL Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting LPL. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: LPL Antibody (F-1): sc-373759
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
LPL Double Nickase Plasmid (h) | sc-400751-NIC | 20 µg | $410.00 | |||
LPL Double Nickase Plasmid (h2) | sc-400751-NIC-2 | 20 µg | $410.00 |
LPL encodes lipoprotein lipase, a secreted and endothelium-anchored enzyme that hydrolyzes triglycerides in circulating chylomicrons and VLDL to release free fatty acids for uptake by muscle and adipose tissue. This activity coordinates lipid uptake, storage, and oxidation programs and intersects with lipid transport and lipoprotein remodeling processes involving apolipoproteins and heparan sulfate proteoglycans. Through its central role in triglyceride-rich lipoprotein clearance, LPL is widely studied in metabolic homeostasis and dyslipidemia-related phenotypes. Altered LPL function or regulation is associated with hypertriglyceridemia and downstream cardiometabolic risk biology, making it a common target for mechanistic studies in lipid metabolism.
LPL Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the LPL locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within LPL. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt LPL function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of LPL-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.